Treatment with the ROS1 inhibitor entrectinib yielded deep and durable responses in patients with ROS1 fusion-positive non–small cell lung cancer (ROS1+ NSCLC), including in those with brain metastases, according to a pooled analysis of three studies.
First-line therapy with the anti-programmed death ligand-1 (PD-L1) monoclonal antibody durvalumab improved overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) compared with platinum-based chemotherapy (CT), according to results from two analyses of the MYSTIC* trial presented at ELCC 2019.
Maintenance immunotherapy with the immune checkpoint inhibitors nivolumab and ipilimumab failed to improve overall survival (OS) in individuals with extensive-stage disease small-cell lung cancer (ED-SCLC), according to CheckMate 451* results presented at ELCC 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Respirology - Malaysia digital copy today!
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.